Baird Rates ICON Public (ICLR) buy, $186 Price Target

Baird analyst Eric Coldwell keeps a buy rating on ICON Public Limited Company while shares change hands close to the $170 mark, a 9.50% upside from the current price.

By EarningsIQ Research Desk · Published Jun 25, 2026, 8:01 AM EDT · Updated Jun 29, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Baird rated ICON Public Limited Company ($ICLR) "buy" with a $186 price target on June 25, 2026.

Since the rating, $ICLR is up 7.5% after 1 week, up 4.9% after 1 month and up 5.7% to date (from the $160.96 close on Jun 25, 2026).

ICLR ICON Public Limited Company

$170.18 -9.80% year to date

Daily close · Oct 16, 2026

Key Points

Baird analyst Eric Coldwell reiterated a buy rating on ICON Public Limited Company (NasdaqGS: ICLR) on June 25, 2026, setting a price target of $186.
Baird's $186 price target implies 9.50% upside from ICON Public Limited Company's ($ICLR) current $169.86 share price.
The stock traded around $169.86 on Thursday, sitting above its 200-day moving average of $147.20 and near its 50-day moving average of $167.30.
Wall Street maintains an overall buy recommendation on the clinical research firm, backed by 16 analyst opinions and a mean price target of $185.25.

Get $ICLR trade alerts by text

We text you when insiders, Congress or big funds trade $ICLR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ICON Public Limited Company alert may contain errors. Disclosures

Baird Keeps Buy Rating on ICON Public Limited Company

Analyst Eric Coldwell at Baird reaffirmed a buy rating on ICON Public Limited Company (NasdaqGS: ICLR) on June 25, 2026, keeping a price target of $186 on the shares. The target sits above where the stock recently changed hands, giving a glimpse into how much upside the firm expects from the clinical research provider.

Analyst rating track record

Baird vs. the S&P 500

YTD return +6.99% hypothetical

All-time return +12.38% S&P 500 +27.32%

vs. S&P 500 -14.94% behind the index

Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.

Where ICON Stock Trades Today

On Thursday, shares of ICON changed hands at $169.86. The stock sits above its 200-day moving average of $147.20 and close to its 50-day moving average of $167.30. Over the past year, the company has traded in a 52-week range between $66.57 and $203.91, reflecting a wide swing in market sentiment for the healthcare provider.

12-month forecast

$ICLR price target

ICON Public Limited Company daily closes and this analyst's $186 target. Not advice.

Recent Analyst Action Across Wall Street

Other major firms have also reviewed their outlooks for the company around the same period. On June 25, 2026, Citigroup maintained its neutral rating while lifting its target to $165 from $140. On that same day, BMO Capital maintained an outperform rating and bumped its target to $187 from $160, while Barclays kept an equal-weight rating with a target of $175. Later in the month, Mizuho maintained an outperform rating with a $190 target on June 26, 2026, and Truist Securities upgraded the stock to a buy on June 30, 2026, setting a $207 target. Truist subsequently raised that target to $209 on July 31, 2026, while Citigroup maintained a neutral rating with a $180 target. More recently, Citigroup maintained a neutral rating with a $175 target on September 18, 2026. Overall, the stock carries a consensus buy recommendation from 16 analysts, with a mean price target of $185.25, a high target of $220, and a low target of $155.

What the Company Does

Headquartered in Dublin, Ireland, ICON Public Limited Company operates as a clinical research organization, offering outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. The firm handles everything from early compound selection to late-stage Phase I through Phase IV clinical studies, helping clients manage data solutions, laboratory testing, and consulting services.

What to Watch at ICON Public Limited Company

Investors will look toward the company's next scheduled earnings report on October 21, 2026, to see how revenue and profit margins evolve. Analyst price targets offer a look into expected future valuations, but they remain subject to change as broader market conditions shift.